Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study.

ABSTRACT:

Background

Several mAb biologic therapies are approved for the treatment of severe asthma. There are limited data examining biologic outcomes in patients with allergy that has been clinically confirmed to exacerbate their asthma symptoms.

Objective

Our aim was to assess rates of asthma exacerbations, exacerbation-related emergency department (ED) visits, and exacerbation-related hospitalizations before and after biologic initiation among adults with severe asthma and confirmed clinically relevant allergy.

Methods

CHRONICLE was an observational study of subspecialist-treated US adults with severe asthma. Annualized rates of asthma exacerbations, exacerbation-related ED visits, and exacerbation-related hospitalizations (6 months before and after initiation of biologic t

SUBMITTER: Chipps BE 

PROVIDER: S-EPMC12661102 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature